According to the announcement on the evening of February 9, Guangzhou Yipinhong Pharmaceutical Co.Ltd(300723) (300723) Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the drug registration certificate approved and issued by the State Drug Administration.
According to the approved drug instructions, nifedipine controlled-release tablets developed by the company are used to treat hypertension and coronary heart disease (chronic stable angina pectoris, i.e. exertional angina pectoris). Nifedipine controlled-release tablets belong to class a products of national medical insurance in 2021. The approved nifedipine controlled-release tablets of the company are registered as class 4 chemicals and are deemed to have passed the consistency evaluation of generic drugs. According to micnet data, in 2020, the total sales scale of nifedipine in China’s urban public hospitals, county-level public hospitals, urban community centers, township health centers (hereinafter referred to as China’s public medical institutions) and China’s urban physical pharmacy terminals exceeded 6 billion yuan.
Yipinhong Pharmaceutical Co.Ltd(300723) said in the announcement that obtaining the registration certificate of nifedipine controlled-release tablets this time indicates that the company has the qualification to sell the drug in the Chinese market, which will further enrich the company’s product pipelines and categories and enhance the company’s competitiveness in the field of chronic diseases.
